At DiaMedica Therapeutics, our goal is to develop innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. Our dedicated team includes investigators and trial participants who work together to advance our therapeutics through the many parts and phases of the trial. Each member of our team plays a critical role in contributing to our understanding of the disease states and demonstrating how potential new therapies can improve treatment options.
Current Clinical Trials
This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare intravenous dosing with subcutaneous dosing. To learn more about this study or to see if you qualify, visit DM199 Ascending Dose Study.
To learn more about DiaMedica Therapeutics' current clinical trials, please visit www.clinicaltrials.gov.